ProCE Banner Activity

CME

Exploring the Progress and Evolving Therapeutic Paradigm in Multiple Myeloma

Video

Watch this on-demand webcast from a June 2023 symposium featuring Joseph Mikhael, MD, MEd, FRCPC, FACP; Shaji K. Kumar, MD; and Noopur Raje, MD, on recent developments in the treatment of multiple myeloma to optimally individualize therapy.

Physicians: Maximum of 2.00 AMA PRA Category 1 Credits

Released: June 21, 2023

Expiration: June 20, 2024

Share

Faculty

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Joseph Mikhael

Joseph Mikhael, MD, MEd, FRCPC, FACP

Professor
Applied Cancer Research and Drug Discovery 
Translational Genomics Research Institute 
Phoenix, Arizona
Chief Medical Officer
International Myeloma Foundation 
HonorHealth Research Institute 
Scottsdale, Arizona

Noopur Raje

Noopur Raje, MD

Director
Center for Multiple Myeloma
Rita Kelly Chair in Oncology
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Karyopharm Therapeutics, Legend Biotech USA, and Pfizer Inc.

AbbVie Inc.

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics Inc.

Legend Biotech USA Inc.

Pfizer, Inc.

Target Audience

This educational program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma.

Program Learning Goal

The goal of this activity is to educate hematologists, oncologists, and other healthcare professionals about recent developments in the treatment of multiple myeloma to optimally individualize therapy.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate emerging clinical data on novel therapeutics and combination treatment strategies for patients with multiple myeloma

  • Initiate timely systemic treatment for appropriate patients based on the latest multiple myeloma diagnostic and staging criteria

  • Develop individualized treatment strategies for patients with newly diagnosed multiple myeloma through consideration of the available clinical data, as well as risk assessment, comorbidities, and patient age/fitness and preferences

  • Select therapeutic strategies with new and emerging agents and novel combination regimens for patients with relapsed/refractory multiple myeloma based on available data, expert recommendations, and individual patient and disease characteristics

  • Identify patients who may be eligible to enroll on a clinical trial of investigational therapies or combination regimens to treat multiple myeloma at all stages of the disease

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji K. Kumar, MD: consultant/advisor: AbbVie, Amgen, Antengene, Arcellx, AstraZeneca, BeiGene, Bluebird Bio, Bristol Myers Squibb, Janssen, Roche-Genentech, K36, Loxo Oncology, Oncopeptides, Pfizer, Sanofi, Secura Biotherapeutics, Takeda; researcher: AbbVie, Allogene, Amgen, AstraZeneca, Bristol Myers Squibb, Carsgen, GSK, Janssen, Regeneron, Roche-Genentech, Takeda.

Joseph Mikhael, MD, MEd, FRCPC, FACP

Professor
Applied Cancer Research and Drug Discovery 
Translational Genomics Research Institute 
Phoenix, Arizona
Chief Medical Officer
International Myeloma Foundation 
HonorHealth Research Institute 
Scottsdale, Arizona

Joseph Mikhael, MD, MEd, FRCPC, FACP: consultant/advisor/speaker: Amgen, Bristol Myers Squibb, Janssen, Karyopharm, Sanofi, Takeda.

Noopur Raje, MD

Director
Center for Multiple Myeloma
Rita Kelly Chair in Oncology
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Noopur Raje, MD: consultant/advisor/speaker: AbbVie, Amgen, Bristol Myers Squibb, Caribou, Janssen, Immuneel, Pfizer; researcher: 2Seventy Bio, Pfizer.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 21, 2023, through June 20, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.